Sanofi (SNY) Non-Current Deferred Tax Liability (2016 - 2025)
Sanofi's Non-Current Deferred Tax Liability history spans 17 years, with the latest figure at $1.9 billion for Q4 2025.
- On a quarterly basis, Non-Current Deferred Tax Liability fell 16.21% to $1.9 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 billion, a 16.21% decrease, with the full-year FY2025 number at $1.9 billion, down 16.21% from a year prior.
- Non-Current Deferred Tax Liability hit $1.9 billion in Q4 2025 for Sanofi, roughly flat from $1.9 billion in the prior quarter.
- Over the last five years, Non-Current Deferred Tax Liability for SNY hit a ceiling of $2.3 billion in Q4 2024 and a floor of $1.7 billion in Q2 2022.
- Historically, Non-Current Deferred Tax Liability has averaged $2.0 billion across 5 years, with a median of $1.9 billion in 2025.
- Biggest five-year swings in Non-Current Deferred Tax Liability: dropped 17.96% in 2022 and later rose 28.38% in 2023.
- Tracing SNY's Non-Current Deferred Tax Liability over 5 years: stood at $1.8 billion in 2021, then grew by 1.54% to $1.9 billion in 2022, then grew by 6.38% to $2.0 billion in 2023, then grew by 15.84% to $2.3 billion in 2024, then decreased by 16.21% to $1.9 billion in 2025.
- Business Quant data shows Non-Current Deferred Tax Liability for SNY at $1.9 billion in Q4 2025, $1.9 billion in Q2 2025, and $2.3 billion in Q4 2024.